x
|
QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
¨
|
TRANSITION REPORT PURSUANT TO
SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
Delaware
(State
or Other Jurisdiction of Incorporation or Organization)
|
75-3142681
(I.R.S.
Employer Identification No.)
|
811
Hansen Way, Palo Alto, California 94303
(Address
of Principal Executive Offices and Zip Code)
|
|
(650)
846-2900
(Registrant’s
telephone number, including area code)
|
|
Not
Applicable
(Former
name, former address and former fiscal year, if changed since last
report)
|
Large accelerated
filer
|
¨
|
Accelerated
filer
|
x
|
Non-accelerated filer
|
¨
(Do not check if a smaller reporting company)
|
Smaller
reporting company
|
¨
|
Page |
4
|
|||
4
|
|||
4
|
|||
5
|
|||
6
|
|||
7
|
|||
33
|
|||
43
|
|||
44
|
|||
45
|
|||
45
|
|||
45
|
|||
45
|
|||
45
|
|||
45
|
|||
45
|
|||
46
|
January
1,
|
October
2,
|
|||||||
2010
|
2009
|
|||||||
Assets
|
||||||||
Current
Assets:
|
||||||||
Cash
and cash equivalents
|
$ | 35,110 | $ | 26,152 | ||||
Restricted
cash
|
1,780 | 1,561 | ||||||
Accounts
receivable, net
|
40,159 | 45,145 | ||||||
Inventories
|
70,895 | 66,996 | ||||||
Deferred
tax assets
|
8,585 | 8,652 | ||||||
Prepaid
and other current assets
|
7,269 | 6,700 | ||||||
Total
current assets
|
163,798 | 155,206 | ||||||
Property,
plant, and equipment, net
|
56,725 | 57,912 | ||||||
Deferred
debt issue costs, net
|
3,282 | 3,609 | ||||||
Intangible
assets, net
|
74,682 | 75,430 | ||||||
Goodwill
|
162,225 | 162,225 | ||||||
Other
long-term assets
|
3,903 | 3,872 | ||||||
Total
assets
|
$ | 464,615 | $ | 458,254 | ||||
Liabilities
and stockholders’ equity
|
||||||||
Current
Liabilities:
|
||||||||
Accounts
payable
|
$ | 20,156 | $ | 22,665 | ||||
Accrued
expenses
|
22,084 | 19,015 | ||||||
Product
warranty
|
3,961 | 3,845 | ||||||
Income
taxes payable
|
4,383 | 4,305 | ||||||
Deferred
income taxes
|
212 | - | ||||||
Advance
payments from customers
|
13,302 | 12,996 | ||||||
Total
current liabilities
|
64,098 | 62,826 | ||||||
Deferred
income taxes, non-current
|
24,342 | 24,726 | ||||||
Long-term
debt, less current portion
|
194,925 | 194,922 | ||||||
Other
long-term liabilities
|
2,071 | 2,227 | ||||||
Total
liabilities
|
285,436 | 284,701 | ||||||
Commitments
and contingencies
|
||||||||
Stockholders’
equity
|
||||||||
Common
stock ($0.01 par value, 90,000 shares authorized; 16,833 and 16,807 shares
issued; 16,627 and 16,601 shares outstanding)
|
168 | 168 | ||||||
Additional
paid-in capital
|
76,571 | 75,630 | ||||||
Accumulated
other comprehensive income
|
1,442 | 598 | ||||||
Retained
earnings
|
103,798 | 99,957 | ||||||
Treasury
stock, at cost (206 shares)
|
(2,800 | ) | (2,800 | ) | ||||
Total
stockholders’ equity
|
179,179 | 173,553 | ||||||
Total
liabilities and stockholders' equity
|
$ | 464,615 | $ | 458,254 |
Quarter Ended
|
||||||||
January 1,
2010
|
January 2,
2009
|
|||||||
Sales
|
$ | 82,767 | $ | 77,146 | ||||
Cost
of sales
|
59,327 | 57,230 | ||||||
Gross
profit
|
23,440 | 19,916 | ||||||
Operating
costs and expenses:
|
||||||||
Research
and development
|
2,556 | 2,183 | ||||||
Selling
and marketing
|
5,040 | 4,989 | ||||||
General
and administrative
|
5,525 | 5,224 | ||||||
Amortization
of acquisition-related intangible assets
|
687 | 694 | ||||||
Total
operating costs and expenses
|
13,808 | 13,090 | ||||||
Operating
income
|
9,632 | 6,826 | ||||||
Interest
expense, net
|
3,881 | 4,455 | ||||||
Income
before income taxes
|
5,751 | 2,371 | ||||||
Income
tax expense (benefit)
|
1,910 | (5,284 | ) | |||||
Net
income
|
$ | 3,841 | $ | 7,655 | ||||
Other
comprehensive income, net of tax
|
||||||||
Net
unrealized gain (loss) on cash flow hedges and minimum pension
liability adjustment
|
844 | (3,879 | ) | |||||
Comprehensive
income
|
$ | 4,685 | $ | 3,776 | ||||
Earnings
per common share - Basic
|
$ | 0.23 | $ | 0.47 | ||||
Earnings
per common share - Diluted
|
$ | 0.21 | $ | 0.44 | ||||
Shares
used to compute earnings per common share - Basic
|
16,452 | 16,269 | ||||||
Shares
used to compute earnings per common share - Diluted
|
17,630 | 17,363 |
Quarter Ended
|
||||||||
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Cash
flows from operating activities
|
||||||||
Net
cash provided by operating activities
|
$ | 9,564 | $ | 4,599 | ||||
Cash
flows from investing activities
|
||||||||
Capital
expenditures
|
(811 | ) | (904 | ) | ||||
Net
cash used in investing activities
|
(811 | ) | (904 | ) | ||||
Cash
flows from financing activities
|
||||||||
Repayments
of debt
|
- | (4,750 | ) | |||||
Proceeds
from issuance of common stock to employees
|
189 | 423 | ||||||
Proceeds
from exercise of stock options
|
14 | 7 | ||||||
Excess
tax benefit on stock option exercises
|
2 | - | ||||||
Net
cash provided by (used in) financing activities
|
205 | (4,320 | ) | |||||
Net
increase (decrease) in cash and cash equivalents
|
8,958 | (625 | ) | |||||
Cash
and cash equivalents at beginning of period
|
26,152 | 28,670 | ||||||
Cash
and cash equivalents at end of period
|
$ | 35,110 | $ | 28,045 | ||||
Supplemental
cash flow disclosures
|
||||||||
Cash
paid for interest
|
$ | 1,054 | $ | 1,503 | ||||
Cash
paid for income taxes, net of refunds
|
$ | 2,273 | $ | 819 |
1.
|
The
Company and a Summary of its Significant Accounting
Policies
|
2.
|
Recently
Issued Accounting Standards
|
January
1,
|
October
2,
|
|||||||
2010
|
2009
|
|||||||
Accounts
receivable
|
$ | 40,275 | $ | 45,240 | ||||
Less:
Allowance for doubtful accounts
|
(116 | ) | (95 | ) | ||||
Accounts
receivable, net
|
$ | 40,159 | $ | 45,145 |
January
1,
|
October
2,
|
|||||||
2010
|
2009
|
|||||||
Raw
material and parts
|
$ | 41,722 | $ | 38,205 | ||||
Work
in process
|
21,525 | 20,542 | ||||||
Finished
goods
|
7,648 | 8,249 | ||||||
$ | 70,895 | $ | 66,996 |
Quarter Ended
|
||||||||
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Balance
at beginning of period
|
$ | 4,068 | $ | 1,928 | ||||
Provision
for loss contracts, charged to cost of sales
|
1,111 | 479 | ||||||
Credit
to cost of sales upon revenue recognition
|
(668 | ) | (685 | ) | ||||
Balance
at end of period
|
$ | 4,511 | $ | 1,722 |
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Inventories
|
$ | 4,391 | $ | 1,581 | ||||
Accrued
expenses
|
120 | 141 | ||||||
$ | 4,511 | $ | 1,722 |
Quarter Ended
|
||||||||
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Beginning
accrued warranty
|
$ | 3,845 | $ | 4,159 | ||||
Actual
costs of warranty claims
|
(1,170 | ) | (1,183 | ) | ||||
Estimates
for product warranty, charged to cost of sales
|
1,286 | 1,014 | ||||||
Ending
accrued warranty
|
$ | 3,961 | $ | 3,990 |
January
1,
|
October
2,
|
|||||||
2010
|
2009
|
|||||||
Unrealized
gain on cash flow hedges, net of tax
|
$ | 1,678 | $ | 828 | ||||
Unrealized
actuarial loss and prior service credit for pension
liability, net of tax
|
(236 | ) | (230 | ) | ||||
$ | 1,442 | $ | 598 |
Level
1
|
Observable
inputs that reflect quoted prices (unadjusted) for identical assets or
liabilities in active markets.
|
Level
2
|
Inputs
reflect quoted prices for identical assets or liabilities in markets that
are not active; quoted prices for similar assets or liabilities in active
markets; inputs other than quoted prices that are observable for the asset
or the liability; or inputs that are derived principally from or
corroborated by observable market data by correlation or other
means.
|
Level
3
|
Unobservable
inputs reflecting the Company’s own assumptions incorporated in valuation
techniques used to determine fair value. These assumptions are required to
be consistent with market participant assumptions that are reasonably
available.
|
Fair
Value Measurements at January 1, 2010 Using
|
|||||||||||||||||
Quoted
Prices in Active Markets for Identical Assets
|
Significant
Other
Observable
Inputs
|
Significant
Unobservable Inputs
|
|||||||||||||||
Total
|
(Level
1)
|
(Level
2)
|
(Level
3)
|
||||||||||||||
Assets:
|
|||||||||||||||||
Money
market and overnight U.S. Government securities1
|
$ | 27,998 | $ | 27,998 | $ | - | $ | - | |||||||||
Mutual
funds2
|
163 | 163 | - | - | |||||||||||||
Foreign
exchange forward derivatives3
|
3,143 | - | 3,143 | - | |||||||||||||
Total
assets at fair value
|
$ | 31,304 | $ | 28,161 | $ | 3,143 | - | ||||||||||
Liabilities:
|
|||||||||||||||||
Interest
rate swap derivative4
|
$ | 1,857 | $ | - | $ | 1,857 | $ | - | |||||||||
Total
liabilities at fair value
|
$ | 1,857 | $ | - | $ | 1,857 | $ | - |
1
The money market and overnight U.S. Government securities are
classified as part of cash and cash equivalents and restricted cash in the
condensed consolidated balance sheet.
|
||||||||||||||||
2
The mutual funds are classified as part of other long-term assets
in the condensed consolidated balance sheet.
|
||||||||||||||||
3
The foreign currency derivatives are classified as part of prepaid
and other current assets in the condensed consolidated balance
sheet.
|
||||||||||||||||
4
The interest rate swap derivatives are classified as part of
accrued expenses and other long-term liabilities in the condensed
consolidated balance sheet.
|
Fair
Value Measurements at October 2, 2009 Using
|
||||||||||||||||
Quoted
Prices in Active Markets for Identical Assets
|
Significant
Other
Observable Inputs
|
Significant
Unobservable Inputs
|
||||||||||||||
Total
|
(Level
1)
|
(Level
2)
|
(Level
3)
|
|||||||||||||
Assets:
|
||||||||||||||||
Money
market and overnight U.S. Government securities1
|
$ | 22,464 | $ | 22,464 | $ | - | $ | - | ||||||||
Mutual
funds2
|
152 | 152 | - | - | ||||||||||||
Foreign
exchange forward derivatives3
|
3,467 | - | 3,467 | - | ||||||||||||
Total
assets at fair value
|
$ | 26,083 | $ | 22,616 | $ | 3,467 | - | |||||||||
Liabilities:
|
||||||||||||||||
Interest
rate swap derivative4
|
$ | 2,323 | $ | - | $ | 2,323 | $ | - | ||||||||
Total
liabilities at fair value
|
$ | 2,323 | $ | - | $ | 2,323 | $ | - |
1
The money market and overnight U.S. Government securities are
classified as part of cash and cash equivalents and restricted cash in the
condensed consolidated balance sheet.
|
||||||||||||||||
2
The mutual funds are classified as part of other long-term assets
in the condensed consolidated balance sheet.
|
||||||||||||||||
3
The foreign currency derivatives are classified as part of prepaid
and other current assets in the condensed consolidated balance
sheet.
|
||||||||||||||||
4
The interest rate swap derivatives are classified as part of
accrued expenses and other long-term liabilities in the condensed
consolidated balance sheet.
|
Asset Derivatives | Liability Derivatives | |||||||||
Balance
Sheet
Location
|
Fair
Value
|
Balance
Sheet
Location
|
Fair
Value
|
|||||||
Derivatives
designated as hedging instruments under SFAS No. 133
|
||||||||||
Interest
rate contracts
|
Prepaid
and other current assets
|
$ | - |
Accrued
expenses
|
$ | (1,539 | ) | |||
Interest
rate contracts
|
Other
long-term assets
|
- |
Other
long-term liabilities
|
(318 | ) | |||||
Forward
contracts
|
Prepaid
and other current assets
|
3,143 |
Accrued
expenses
|
- | ||||||
Total derivatives designated as hedging instruments under SFAS No. 133 | $ | 3,143 | $ | (1,857 | ) |
Derivatives
in Statement 133 Cash Flow Hedging Relationships
|
Amount
of
Gain
(Loss) Recognized
in
OCI on Derivative
(Effective
Portion)
|
Location
of
Gain
(Loss) Reclassified from Accumulated
OCI
into Income
(Effective
Portion)
|
Amount
of
Gain
(Loss) Reclassified from Accumulated OCI into Income
(Effective
Portion)
|
Location
of
Gain
(Loss) Recognized in Income on Derivative (Ineffective and Excluded
Portion)
|
Amount
of Gain (Loss) Recognized in Income on Derivative (Ineffective and
Excluded Portion )
|
||||||||||
Interest
rate contracts
|
$ | (84 | ) |
Interest
expense, net
|
$ | (550 | ) |
Interest
expense, net
|
$ | (10 | ) | ||||
Forward
contracts
|
752 |
Cost
of sales
|
(75 | ) |
General
and administrative
|
2 |
(a)
|
||||||||
|
Research
and development
|
39 | |||||||||||||
|
Selling
and marketing
|
17 | |||||||||||||
|
General
and administrative
|
22 | |||||||||||||
Total
|
$ | 668 | $ | (547 | ) | $ | (8 | ) |
(a)
The amount of gain recognized in income represents a $5
gain related to the ineffective portion of the hedging relationships,
net of $3 loss related to the amount excluded from the
assessment of hedge effectiveness.
|
Fiscal
Year
|
Operating
Leases
|
|||
2010
(remaining nine months)
|
$ | 1,442 | ||
2011
|
792 | |||
2012
|
610 | |||
2013
|
451 | |||
2014
|
325 | |||
Thereafter
|
2,602 | |||
$ | 6,222 |
Fiscal
Year
|
Purchase
Contracts
|
|||
2010
(remaining nine months)
|
$ | 29,766 | ||
2011
|
5,314 | |||
2012
|
213 | |||
2013
|
- | |||
2014
|
- | |||
$ | 35,293 |
Oustanding Options
|
Exercisable Options
|
|||||||||||||||||||||||||||||||
Number of Shares
|
Weighted-Average Exercise
Price
|
Weighted-Average Remaining Contractual Term
(Years)
|
Aggregate Intrinsic Value
|
Number of Shares
|
Weighted-Average Exercise
Price
|
Weighted-Average Remaining Contractual Term
(Years)
|
Aggregate Intrinsic Value
|
|||||||||||||||||||||||||
Balance
at October 2, 2009
|
3,382,763 | $ | 6.38 | 4.95 | $ | 20,362 | 2,845,996 | $ | 4.73 | 4.43 | $ | 20,227 | ||||||||||||||||||||
Granted
|
108,000 | 9.66 | ||||||||||||||||||||||||||||||
Exercised
|
(3,073 | ) | 4.32 | |||||||||||||||||||||||||||||
Forfeited
or cancelled
|
(9,250 | ) | 16.28 | |||||||||||||||||||||||||||||
Balance
at January 1, 2010
|
3,478,440 | $ | 6.46 | 4.86 | $ | 25,930 | 2,954,106 | $ | 5.13 | 4.30 | $ | 25,194 |
Number of Shares
|
Weighted-Average Grant-Date Fair Value Per
Share
|
|||||||
Nonvested
at October 2, 2009
|
218,298 | $ | 11.27 | |||||
Granted
|
140,800 | $ | 9.66 | |||||
Vested
|
(19,525 | ) | $ | 16.79 | ||||
Forfeited
|
(2,050 | ) | $ | 10.76 | ||||
Nonvested
at January 1, 2010
|
337,523 | $ | 10.28 |
Expected
term (in years)
|
7.79 | |||
Expected
volatility
|
60.50 | % | ||
Risk-free
rate
|
3.00 | % | ||
Dividend
yield
|
0 | % |
Contractual
term (in years)
|
10.00 | |||
Expected
volatility
|
51.50 | % | ||
Risk-free
rate
|
3.53 | % | ||
Dividend
yield
|
0 | % |
Expected
volatility
|
51.50 | % | ||
Risk-free
rate
|
3.54 | % | ||
Dividend
yield
|
0 | % |
Quarter Ended
|
||||||||
January 1,
2010
|
January 2,
2009
|
|||||||
Share-based
compensation cost recognized in the income
statement by caption:
|
||||||||
Cost
of sales
|
$ | 133 | $ | 117 | ||||
Research
and development
|
49 | 42 | ||||||
Selling
and marketing
|
73 | 68 | ||||||
General
and administrative
|
475 | 394 | ||||||
$ | 730 | $ | 621 | |||||
Share-based
compensation cost capitalized in inventory
|
$ | 141 | $ | 124 | ||||
Share-based
compensation cost remaining in inventory at end of
period
|
$ | 94 | $ | 83 | ||||
Share-based
compensation expense by type of award:
|
||||||||
Stock
options
|
$ | 456 | $ | 418 | ||||
Restricted
stock and units
|
241 | 168 | ||||||
Stock
purchase plan
|
33 | 35 | ||||||
$ | 730 | $ | 621 |
Quarter Ended
|
||||||||
January 1,
2010
|
January 2,
20091
|
|||||||
Basic
Earnings per Share
|
||||||||
Net
income
|
$ | 3,841 | $ | 7,655 | ||||
Income
allocated to participating securities
|
(57 | ) | (72 | ) | ||||
Net
income available to common shareholders
|
$ | 3,784 | $ | 7,583 | ||||
Basic
weighted average common shares outstanding
|
16,452 | 16,269 | ||||||
Net
income per common share - Basic
|
$ | 0.23 | $ | 0.47 | ||||
Diluted
Earnings per Share
|
||||||||
Net
income
|
$ | 3,841 | $ | 7,655 | ||||
Income
allocated to participating securities
|
(57 | ) | (72 | ) | ||||
Net
income available to common shareholders
|
$ | 3,784 | $ | 7,583 | ||||
Basic
weighted average common shares outstanding
|
16,452 | 16,269 | ||||||
Effect
of dilutive stock options
|
1,178 | 1,094 | ||||||
Diluted
weighted averages common shares outstanding
|
17,630 | 17,363 | ||||||
Net
income per common share - Diluted
|
$ | 0.21 | $ | 0.44 |
1
Restated in accordance with ASC 260.
|
Quarter Ended
|
||||||||
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Sales
from external customers
|
||||||||
VED
|
$ | 59,077 | $ | 55,628 | ||||
Satcom
equipment
|
20,127 | 17,451 | ||||||
Other
|
3,563 | 4,067 | ||||||
$ | 82,767 | $ | 77,146 | |||||
Intersegment
product transfers
|
||||||||
VED
|
$ | 6,113 | $ | 5,365 | ||||
Satcom
equipment
|
- | 9 | ||||||
$ | 6,113 | $ | 5,374 | |||||
EBITDA
|
||||||||
VED
|
$ | 12,719 | $ | 10,351 | ||||
Satcom
equipment
|
2,728 | 1,363 | ||||||
Other
|
(3,080 | ) | (2,190 | ) | ||||
$ | 12,367 | $ | 9,524 |
|
•
|
EBITDA
is a component of the measures used by the Company’s board of directors
and management team to evaluate the Company’s operating
performance;
|
|
•
|
the
Company’s Senior Credit Facilities contain a covenant that requires the
Company to maintain a senior secured leverage ratio that contains EBITDA
as a component, and the Company’s management team uses EBITDA to monitor
compliance with this covenant;
|
|
•
|
EBITDA
is a component of the measures used by the Company’s management team to
make day-to-day operating
decisions;
|
|
•
|
EBITDA
facilitates comparisons between the Company’s operating results and those
of competitors with different capital structures and, therefore, is a
component of the measures used by the Company’s management to facilitate
internal comparisons to competitors’ results and the Company’s industry in
general; and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by the Company of certain targets that contain EBITDA as a
component.
|
Quarter Ended
|
||||||||
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Operating
income
|
||||||||
VED
|
$ | 11,232 | $ | 8,923 | ||||
Satcom
equipment
|
2,549 | 1,172 | ||||||
Other
|
(4,149 | ) | (3,269 | ) | ||||
$ | 9,632 | $ | 6,826 |
Quarter Ended
|
||||||||
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Net
income
|
$ | 3,841 | $ | 7,655 | ||||
Depreciation
and amortization
|
2,735 | 2,698 | ||||||
Interest
expense, net
|
3,881 | 4,455 | ||||||
Income
tax expense (benefit)
|
1,910 | (5,284 | ) | |||||
EBITDA
|
$ | 12,367 | $ | 9,524 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Assets
|
||||||||||||||||||||||||
Current
assets:
|
||||||||||||||||||||||||
Cash
and cash equivalents
|
$ | 82 | $ | 18,413 | $ | 845 | $ | 15,770 | $ | - | $ | 35,110 | ||||||||||||
Restricted
cash
|
- | - | 1,687 | 93 | - | 1,780 | ||||||||||||||||||
Accounts
receivable, net
|
- | 15,164 | 10,576 | 14,419 | - | 40,159 | ||||||||||||||||||
Inventories
|
- | 43,548 | 8,083 | 19,866 | (602 | ) | 70,895 | |||||||||||||||||
Deferred
tax assets
|
- | 8,566 | 2 | 17 | - | 8,585 | ||||||||||||||||||
Intercompany
receivable
|
- | 18,156 | 8,027 | - | (26,183 | ) | - | |||||||||||||||||
Prepaid
and other current assets
|
25 | 5,664 | 494 | 1,086 | - | 7,269 | ||||||||||||||||||
Total
current assets
|
107 | 109,511 | 29,714 | 51,251 | (26,785 | ) | 163,798 | |||||||||||||||||
Property,
plant and equipment, net
|
- | 41,083 | 2,997 | 12,645 | - | 56,725 | ||||||||||||||||||
Deferred
debt issue costs, net
|
330 | 2,952 | - | - | - | 3,282 | ||||||||||||||||||
Intangible
assets, net
|
- | 54,439 | 13,331 | 6,912 | - | 74,682 | ||||||||||||||||||
Goodwill
|
- | 93,307 | 20,973 | 47,945 | - | 162,225 | ||||||||||||||||||
Other
long-term assets
|
- | 3,676 | 227 | - | - | 3,903 | ||||||||||||||||||
Intercompany
notes receivable
|
- | 1,035 | - | - | (1,035 | ) | - | |||||||||||||||||
Investment
in subsidiaries
|
217,182 | 111,142 | - | - | (328,324 | ) | - | |||||||||||||||||
Total
assets
|
$ | 217,619 | $ | 417,145 | $ | 67,242 | $ | 118,753 | $ | (356,144 | ) | $ | 464,615 | |||||||||||
Liabilities
and stockholders' equity
|
||||||||||||||||||||||||
Current
liabilities:
|
||||||||||||||||||||||||
Accounts
payable
|
$ | - | $ | 9,254 | $ | 1,726 | $ | 9,176 | $ | - | $ | 20,156 | ||||||||||||
Accrued
expenses
|
336 | 16,675 | 1,714 | 3,359 | - | 22,084 | ||||||||||||||||||
Product
warranty
|
- | 1,952 | 524 | 1,485 | - | 3,961 | ||||||||||||||||||
Income
taxes payable
|
- | 1,398 | 177 | 2,808 | - | 4,383 | ||||||||||||||||||
Deferred
income taxes
|
- | - | - | 212 | - | 212 | ||||||||||||||||||
Advance
payments from customers
|
- | 6,869 | 4,891 | 1,542 | - | 13,302 | ||||||||||||||||||
Intercompany
payable
|
26,179 | - | - | 4 | (26,183 | ) | - | |||||||||||||||||
Total
current liabilities
|
26,515 | 36,148 | 9,032 | 18,586 | (26,183 | ) | 64,098 | |||||||||||||||||
Deferred
income taxes, non-current
|
- | 20,331 | - | 4,011 | - | 24,342 | ||||||||||||||||||
Intercompany
notes payable
|
- | - | - | 1,035 | (1,035 | ) | - | |||||||||||||||||
Long-term
debt, less current portion
|
11,925 | 183,000 | - | - | - | 194,925 | ||||||||||||||||||
Other
long-term liabilities
|
- | 1,561 | 36 | 474 | - | 2,071 | ||||||||||||||||||
Total
liabilities
|
38,440 | 241,040 | 9,068 | 24,106 | (27,218 | ) | 285,436 | |||||||||||||||||
Common
stock
|
168 | - | - | - | - | 168 | ||||||||||||||||||
Parent
investment
|
- | 53,028 | 43,167 | 58,759 | (154,954 | ) | - | |||||||||||||||||
Additional
paid-in capital
|
76,571 | - | - | (8,211 | ) | 8,211 | 76,571 | |||||||||||||||||
Accumulated
other comprehensive loss
|
1,442 | 1,442 | - | 590 | (2,032 | ) | 1,442 | |||||||||||||||||
Retained
earnings
|
103,798 | 121,635 | 15,007 | 43,509 | (180,151 | ) | 103,798 | |||||||||||||||||
Treasury
stock, at cost
|
(2,800 | ) | - | - | - | - | (2,800 | ) | ||||||||||||||||
Total
stockholders’ equity
|
179,179 | 176,105 | 58,174 | 94,647 | (328,926 | ) | 179,179 | |||||||||||||||||
Total
liabilities and stockholders' equity
|
$ | 217,619 | $ | 417,145 | $ | 67,242 | $ | 118,753 | $ | (356,144 | ) | $ | 464,615 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Assets
|
||||||||||||||||||||||||
Cash
and cash equivalents
|
$ | 10 | $ | 15,055 | $ | 759 | $ | 10,328 | $ | - | $ | 26,152 | ||||||||||||
Restricted
cash
|
- | - | 1,467 | 94 | - | 1,561 | ||||||||||||||||||
Accounts
receivable, net
|
- | 18,456 | 12,581 | 14,108 | - | 45,145 | ||||||||||||||||||
Inventories
|
- | 41,877 | 7,622 | 18,117 | (620 | ) | 66,996 | |||||||||||||||||
Deferred
tax assets
|
- | 8,494 | 2 | 156 | - | 8,652 | ||||||||||||||||||
Intercompany
receivable
|
- | 9,033 | 6,751 | 10,534 | (26,318 | ) | - | |||||||||||||||||
Prepaid
and other current assets
|
- | 5,396 | 475 | 829 | - | 6,700 | ||||||||||||||||||
Total
current assets
|
10 | 98,311 | 29,657 | 54,166 | (26,938 | ) | 155,206 | |||||||||||||||||
Property,
plant and equipment, net
|
- | 42,048 | 3,001 | 12,863 | - | 57,912 | ||||||||||||||||||
Deferred
debt issue costs, net
|
344 | 3,265 | - | - | - | 3,609 | ||||||||||||||||||
Intangible
assets, net
|
- | 54,891 | 13,477 | 7,062 | - | 75,430 | ||||||||||||||||||
Goodwill
|
- | 93,307 | 20,973 | 47,945 | - | 162,225 | ||||||||||||||||||
Other
long-term assets
|
- | 3,645 | 227 | - | - | 3,872 | ||||||||||||||||||
Intercompany
notes receivable
|
- | 1,035 | - | - | (1,035 | ) | - | |||||||||||||||||
Investment
in subsidiaries
|
211,575 | 114,416 | - | - | (325,991 | ) | - | |||||||||||||||||
Total
assets
|
$ | 211,929 | $ | 410,918 | $ | 67,335 | $ | 122,036 | $ | (353,964 | ) | $ | 458,254 | |||||||||||
Liabilities
and stockholders' equity
|
||||||||||||||||||||||||
Accounts
payable
|
$ | (1 | ) | $ | 11,100 | $ | 2,730 | $ | 8,836 | $ | - | $ | 22,665 | |||||||||||
Accrued
expenses
|
137 | 13,293 | 1,634 | 3,951 | - | 19,015 | ||||||||||||||||||
Product
warranty
|
- | 1,893 | 452 | 1,500 | - | 3,845 | ||||||||||||||||||
Income
taxes payable
|
- | 1,683 | 151 | 2,471 | - | 4,305 | ||||||||||||||||||
Advance
payments from customers
|
- | 7,389 | 4,368 | 1,239 | - | 12,996 | ||||||||||||||||||
Intercompany
payable
|
26,318 | - | - | - | (26,318 | ) | - | |||||||||||||||||
Total
current liabilities
|
26,454 | 35,358 | 9,335 | 17,997 | (26,318 | ) | 62,826 | |||||||||||||||||
Deferred
income taxes, non-current
|
- | 20,342 | - | 4,384 | - | 24,726 | ||||||||||||||||||
Intercompany
notes payable
|
- | - | - | 1,035 | (1,035 | ) | - | |||||||||||||||||
Long-term
debt, less current portion
|
11,922 | 183,000 | - | - | - | 194,922 | ||||||||||||||||||
Other
long-term liabilities
|
- | 1,720 | 36 | 471 | - | 2,227 | ||||||||||||||||||
Total
liabilities
|
38,376 | 240,420 | 9,371 | 23,887 | (27,353 | ) | 284,701 | |||||||||||||||||
Common
stock
|
168 | - | - | - | - | 168 | ||||||||||||||||||
Parent
investment
|
- | 52,241 | 43,167 | 58,615 | (154,023 | ) | - | |||||||||||||||||
Additional
paid-in capital
|
75,630 | - | - | (211 | ) | 211 | 75,630 | |||||||||||||||||
Accumulated
other comprehensive gain (loss)
|
598 | 598 | - | (223 | ) | (375 | ) | 598 | ||||||||||||||||
Retained
earnings
|
99,957 | 117,659 | 14,797 | 39,968 | (172,424 | ) | 99,957 | |||||||||||||||||
Treasury
stock
|
(2,800 | ) | - | - | - | - | (2,800 | ) | ||||||||||||||||
Total
stockholders’ equity
|
173,553 | 170,498 | 57,964 | 98,149 | (326,611 | ) | 173,553 | |||||||||||||||||
Total
liabilities and stockholders' equity
|
$ | 211,929 | $ | 410,918 | $ | 67,335 | $ | 122,036 | $ | (353,964 | ) | $ | 458,254 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 47,936 | $ | 17,419 | $ | 37,119 | $ | (19,707 | ) | $ | 82,767 | |||||||||||
Cost
of sales
|
- | 36,880 | 14,783 | 27,389 | (19,725 | ) | 59,327 | |||||||||||||||||
Gross
profit
|
- | 11,056 | 2,636 | 9,730 | 18 | 23,440 | ||||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 557 | 20 | 1,979 | - | 2,556 | ||||||||||||||||||
Selling
and marketing
|
- | 1,593 | 1,173 | 2,274 | - | 5,040 | ||||||||||||||||||
General
and administrative
|
1 | 3,323 | 987 | 1,214 | - | 5,525 | ||||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 390 | 146 | 151 | - | 687 | ||||||||||||||||||
Total
operating costs and expenses
|
1 | 5,863 | 2,326 | 5,618 | - | 13,808 | ||||||||||||||||||
Operating
income
|
(1 | ) | 5,193 | 310 | 4,112 | 18 | 9,632 | |||||||||||||||||
Interest
expense, net
|
216 | 3,638 | (1 | ) | 28 | - | 3,881 | |||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(217 | ) | 1,555 | 311 | 4,084 | 18 | 5,751 | |||||||||||||||||
Income
tax (benefit) expense
|
(82 | ) | 1,348 | 101 | 543 | - | 1,910 | |||||||||||||||||
Equity
in income of subsidiaries
|
3,976 | 3,769 | - | - | (7,745 | ) | - | |||||||||||||||||
Net
income
|
$ | 3,841 | $ | 3,976 | $ | 210 | $ | 3,541 | $ | (7,727 | ) | $ | 3,841 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Sales
|
$ | - | $ | 46,215 | $ | 19,707 | $ | 31,723 | $ | (20,499 | ) | $ | 77,146 | |||||||||||
Cost
of sales
|
- | 36,267 | 16,613 | 24,773 | (20,423 | ) | 57,230 | |||||||||||||||||
Gross
profit
|
- | 9,948 | 3,094 | 6,950 | (76 | ) | 19,916 | |||||||||||||||||
Operating
costs and expenses:
|
||||||||||||||||||||||||
Research
and development
|
- | 684 | - | 1,499 | - | 2,183 | ||||||||||||||||||
Selling
and marketing
|
- | 1,742 | 1,247 | 2,000 | - | 4,989 | ||||||||||||||||||
General
and administrative
|
- | 3,730 | 1,023 | 471 | - | 5,224 | ||||||||||||||||||
Amortization
of acquisition-related intangible assets
|
- | 390 | 153 | 151 | - | 694 | ||||||||||||||||||
Total
operating costs and expenses
|
- | 6,546 | 2,423 | 4,121 | - | 13,090 | ||||||||||||||||||
Operating
income
|
- | 3,402 | 671 | 2,829 | (76 | ) | 6,826 | |||||||||||||||||
Interest
expense (income), net
|
278 | 4,153 | (5 | ) | 29 | - | 4,455 | |||||||||||||||||
(Loss)
income before income tax expense
|
||||||||||||||||||||||||
and
equity in income of subsidiaries
|
(278 | ) | (751 | ) | 676 | 2,800 | (76 | ) | 2,371 | |||||||||||||||
Income
tax (benefit) expense
|
(105 | ) | (3,834 | ) | 115 | (1,460 | ) | - | (5,284 | ) | ||||||||||||||
Equity
in income of subsidiaries
|
7,828 | 4,745 | - | - | (12,573 | ) | - | |||||||||||||||||
Net
income
|
$ | 7,655 | $ | 7,828 | $ | 561 | $ | 4,260 | $ | (12,649 | ) | $ | 7,655 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Cash
flows from operating activities
|
||||||||||||||||||||||||
Net
cash (used in) provided by operating activities
|
$ | (131 | ) | $ | 3,972 | $ | 187 | $ | 5,536 | $ | - | $ | 9,564 | |||||||||||
Cash
flows from investing activities
|
||||||||||||||||||||||||
Capital
expenditures
|
- | (616 | ) | (101 | ) | (94 | ) | - | (811 | ) | ||||||||||||||
Net
cash used in investing activities
|
- | (616 | ) | (101 | ) | (94 | ) | - | (811 | ) | ||||||||||||||
Cash
flows from financing activities
|
||||||||||||||||||||||||
Proceeds
from issuance of common stock to employees
|
189 | - | - | - | - | 189 | ||||||||||||||||||
Proceeds
from exercise of stock options
|
14 | - | - | - | - | 14 | ||||||||||||||||||
Excess
tax benefit on stock option exercises
|
- | 2 | - | - | - | 2 | ||||||||||||||||||
Net
cash provided by financing activities
|
203 | 2 | - | - | - | 205 | ||||||||||||||||||
Net
increase in cash and cash equivalents
|
72 | 3,358 | 86 | 5,442 | - | 8,958 | ||||||||||||||||||
Cash
and cash equivalents at beginning of period
|
10 | 15,055 | 759 | 10,328 | - | 26,152 | ||||||||||||||||||
Cash
and cash equivalents at end of period
|
$ | 82 | $ | 18,413 | $ | 845 | $ | 15,770 | $ | - | $ | 35,110 |
Parent
|
Issuer
|
Guarantor
|
Non-Guarantor
|
Consolidating
|
Consolidated
|
|||||||||||||||||||
(CPI
Int'l)
|
(CPI)
|
Subsidiaries
|
Subsidiaries
|
Eliminations
|
Total
|
|||||||||||||||||||
Cash
flows from operating activities
|
||||||||||||||||||||||||
Net
cash (used in) provided by operating activities
|
$ | (378 | ) | $ | 2,477 | $ | 1,505 | $ | 995 | $ | - | $ | 4,599 | |||||||||||
Cash
flows from investing activities
|
||||||||||||||||||||||||
Capital
expenditures
|
- | (835 | ) | - | (69 | ) | - | (904 | ) | |||||||||||||||
Net
cash used in investing activities
|
- | (835 | ) | - | (69 | ) | - | (904 | ) | |||||||||||||||
Cash
flows from financing activities
|
||||||||||||||||||||||||
Repayments
of debt
|
- | (4,750 | ) | - | - | - | (4,750 | ) | ||||||||||||||||
Proceeds
from issuance of common stock to employees
|
423 | - | - | - | - | 423 | ||||||||||||||||||
Proceeds
from exercise of stock options
|
7 | - | - | - | - | 7 | ||||||||||||||||||
Intercompany
dividends / debt
|
- | (8,000 | ) | - | 8,000 | - | - | |||||||||||||||||
Net
cash provided by (used in) financing activities
|
430 | (12,750 | ) | - | 8,000 | - | (4,320 | ) | ||||||||||||||||
Net
increase (decrease) in cash and cash equivalents
|
52 | (11,108 | ) | 1,505 | 8,926 | - | (625 | ) | ||||||||||||||||
Cash
and cash equivalents at beginning of period
|
84 | 26,272 | 493 | 1,821 | - | 28,670 | ||||||||||||||||||
Cash
and cash equivalents at end of period
|
$ | 136 | $ | 15,164 | $ | 1,998 | $ | 10,747 | $ | - | $ | 28,045 |
Quarter
Ended
|
||||||||||||||||||||||||
January
1,
2010
|
January
2,
2009
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Orders
|
Amount
|
Orders
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 33.5 | 36 | % | $ | 32.0 | 47 | % | $ | 1.5 | 5 | % | ||||||||||||
Medical
|
15.6 | 17 | 10.4 | 16 | 5.2 | 50 | ||||||||||||||||||
Communications
|
35.1 | 38 | 17.4 | 26 | 17.7 | 102 | ||||||||||||||||||
Industrial
|
3.8 | 4 | 6.4 | 10 | (2.6 | ) | (41 | ) | ||||||||||||||||
Scientific
|
4.7 | 5 | 0.8 | 1 | 3.9 | 490 | ||||||||||||||||||
Total
|
$ | 92.7 | 100 | % | $ | 67.0 | 100 | % | $ | 25.7 | 38 | % |
·
|
Radar and Electronic
Warfare: The majority of our products in the radar and electronic
warfare markets are for domestic and international defense and government
end uses. Orders in these markets are characterized by many smaller orders
in the $0.5 million to $3.0 million range by product or program, and the
timing of these orders may vary from year to year. On a combined basis,
orders for the radar and electronic warfare markets increased
approximately 5% from an aggregate of $32.0 million in the first quarter
of fiscal year 2009 to an aggregate of $33.5 million in the first quarter
of fiscal year 2010. The increase in orders for these combined markets
resulted primarily from an increase in demand for products to support
various weather radar programs and the Aegis weapons system. These
increases were partially offset by decreases in orders to support various
other radar and electronic warfare programs, in part due to the timing of
those programs.
|
·
|
Medical: Orders for our
medical products consist of orders for medical imaging applications, such
as x-ray imaging, magnetic resonance imaging (“MRI”) and positron emission
tomography (“PET”) applications, and for radiation therapy applications
for the treatment of cancer. The 50% increase in medical orders resulted
from demand increasing for products to support MRI applications and demand
improving to more normal levels for products to support x-ray imaging
applications.
|
·
|
Communications: Orders
for our communications products consist of orders for commercial
communications applications and military communications applications. The
102% increase in communications orders was due in equal part to increases
in orders to support commercial communications applications, such as
high-capacity broadband systems, and increases in orders to support
various military communications applications. Military communications is a
relatively new sector of the overall communications market for us, and we
expect our participation in military communications programs to continue
to grow.
|
·
|
Industrial: Orders in
the industrial market are cyclical and are generally tied to the state of
the economy. The $2.6 million decrease in industrial orders was primarily
due to the timing of orders for products used in instrumentation
applications.
|
·
|
Scientific: Orders in
the scientific market are historically one-time projects and can fluctuate
significantly from period to period. The $3.9 million increase in
scientific orders was primarily the result of the receipt of orders for
products to support fusion research at domestic scientific
laboratories.
|
Quarter
Ended
|
|||||||||||||||||||||
January
1,
2010
|
January
2,
2009
|
Increase
(Decrease)
|
|||||||||||||||||||
%
of
|
%
of
|
||||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
|||||||||||||||||
Sales
|
$ | 82.8 | 100.0 | % | $ | 77.1 | 100.0 | % | $ | 5.7 | |||||||||||
Cost
of sales
|
59.3 | 71.6 | 57.2 | 74.2 | 2.1 | ||||||||||||||||
Gross
profit
|
23.4 | 28.3 | 19.9 | 25.8 | 3.5 | ||||||||||||||||
Research
and development
|
2.6 | 3.1 | 2.2 | 2.9 | 0.4 | ||||||||||||||||
Selling
and marketing
|
5.0 | 6.0 | 5.0 | 6.5 | - | ||||||||||||||||
General
and administrative
|
5.5 | 6.6 | 5.2 | 6.7 | 0.3 | ||||||||||||||||
Amortization
of acquisition-related
intangibles
|
0.7 | 0.8 | 0.7 | 0.9 | - | ||||||||||||||||
Operating
income
|
9.6 | 11.6 | 6.8 | 8.8 | 2.8 | ||||||||||||||||
Interest
expense, net
|
3.9 | 4.7 | 4.5 | 5.8 | (0.6 | ) | |||||||||||||||
Income
before taxes
|
5.8 | 7.0 | 2.4 | 3.1 | 3.4 | ||||||||||||||||
Income
tax expense (benefit)
|
1.9 | 2.3 | (5.3 | ) | (6.9 | ) | 7.2 | ||||||||||||||
Net
income
|
$ | 3.8 | 4.6 | % | $ | 7.7 | 10.0 | % | $ | (3.9 | ) | ||||||||||
Other
Data:
|
|||||||||||||||||||||
EBITDA
(a)
|
$ | 12.4 | 15.0 | % | $ | 9.5 | 12.3 | % | $ | 2.9 | |||||||||||
Note: Totals
may not equal the sum of the components due to independent rounding.
Percentages are calculated based on rounded dollar amounts
presented.
|
(a)
|
EBITDA
represents earnings before net interest expense, provision for income
taxes and depreciation and amortization. For the reasons listed below, we
believe that U.S. generally accepted accounting principles (“GAAP”) based
financial information for leveraged businesses such as ours should be
supplemented by EBITDA so that investors better understand our financial
performance in connection with their analysis of our
business:
|
|
•
|
EBITDA
is a component of the measures used by our board of directors and
management team to evaluate our operating
performance;
|
|
•
|
our
senior credit facilities contain a covenant that requires us to maintain a
senior secured leverage ratio that contains EBITDA as a component, and our
management team uses EBITDA to monitor compliance with this
covenant;
|
|
•
|
EBITDA
is a component of the measures used by our management team to make
day-to-day operating decisions;
|
|
•
|
EBITDA
facilitates comparisons between our operating results and those of
competitors with different capital structures and, therefore, is a
component of the measures used by the management to facilitate internal
comparisons to competitors’ results and our industry in general;
and
|
|
•
|
the
payment of management bonuses is contingent upon, among other things, the
satisfaction by us of certain targets that contain EBITDA as a
component.
|
|
Other
companies may define EBITDA differently and, as a result, our measure of
EBITDA may not be directly comparable to EBITDA of other companies.
Although we use EBITDA as a financial measure to assess the performance of
our business, the use of EBITDA is limited because it does not include
certain material costs, such as interest and taxes, necessary to operate
our business. When analyzing our performance, EBITDA should be considered
in addition to, and not as a substitute for or superior to, net income,
cash flows from operating activities or other statements of income or
statements of cash flows data prepared in accordance with
GAAP.
|
|
For
a reconciliation of Net Income to EBITDA, see Note 10 of the accompanying
unaudited condensed consolidated financial
statements.
|
Quarter
Ended
|
||||||||||||||||||||||||
January
1,
2010
|
January
2,
2009
|
Increase
(Decrease)
|
||||||||||||||||||||||
%
of
|
%
of
|
|||||||||||||||||||||||
Amount
|
Sales
|
Amount
|
Sales
|
Amount
|
Percent
|
|||||||||||||||||||
Radar
and Electronic Warfare
|
$ | 28.2 | 34 | % | $ | 28.0 | 36 | % | $ | 0.2 | 1 | % | ||||||||||||
Medical
|
19.4 | 23 | 15.8 | 21 | 3.6 | 23 | ||||||||||||||||||
Communications
|
28.7 | 35 | 26.2 | 34 | 2.5 | 9 | ||||||||||||||||||
Industrial
|
5.2 | 6 | 5.5 | 7 | (0.3 | ) | (5 | ) | ||||||||||||||||
Scientific
|
1.3 | 2 | 1.6 | 2 | (0.3 | ) | (18 | ) | ||||||||||||||||
Total
|
$ | 82.8 | 100 | % | $ | 77.1 | 100 | % | $ | 5.7 | 7 | % |
·
|
Radar and Electronic Warfare:
The majority of our products in the radar and electronic warfare
markets are for domestic and international defense and government end
uses. The timing of orders receipts and subsequent shipments in these
markets may vary from year to year. On a combined basis, sales for these
two markets totaled $28.2 million in the first quarter of fiscal year
2010, essentially unchanged from the $28.0 million in the first quarter of
fiscal year 2009.
|
·
|
Medical: Sales of our
medical products consist of sales for medical imaging applications, such
as x-ray imaging, MRI and PET applications, and for radiation therapy
applications for the treatment of cancer. The 23% increase in sales of our
medical products in the first quarter of fiscal year 2010 was primarily
due to sales increasing for products to support MRI applications and sales
improving to more normal levels for products to support x-ray imaging
applications.
|
·
|
Communications: Sales of
our communications products consist of sales for commercial communications
applications and military communications applications. The 9% increase in
sales in the communications market was due to increases in sales to
support a variety of commercial and military communications applications.
Military communications is a relatively new sector of the overall
communications market for us, and we expect our participation in military
communications programs to continue to
grow.
|
·
|
Industrial: Sales in the
industrial market are cyclical and are generally tied to the state of the
economy. The $0.3 million decrease in sales of industrial products in the
first quarter of fiscal year 2010 was primarily due to decreases in sales
to support semiconductor wafer fabrication applications, and was partially
offset by an increase in sales to support cargo screening
applications.
|
·
|
Scientific: Sales in the
scientific market are historically one-time projects and can fluctuate
significantly from period to period. The $0.3 million decrease in
scientific sales was primarily the result of decreased product shipments
for the Spallation Neutron Source at Oakridge National Laboratory. We
received approximately $5 million in orders for this program in fiscal
year 2007 and completed our shipments of products for this program in
fiscal year 2009.
|
Quarter Ended
|
||||||||
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Company
sponsored
|
$ | 2.6 | $ | 2.2 | ||||
Customer
sponsored, charged to cost of sales
|
3.7 | 3.2 | ||||||
$ | 6.3 | $ | 5.4 |
January
1,
|
October
2,
|
|||||||
2010
|
2009
|
|||||||
Cash
and cash equivalents
|
$ | 35.1 | $ | 26.2 | ||||
Working
capital
|
$ | 99.7 | $ | 92.4 |
Quarter
Ended
|
||||||||
January
1,
|
January
2,
|
|||||||
2010
|
2009
|
|||||||
Net
cash provided by operating activities
|
$ | 9.6 | $ | 4.6 | ||||
Net
cash used in investing activities
|
(0.8 | ) | (0.9 | ) | ||||
Net
cash provided by (used in) financing activities
|
0.2 | (4.3 | ) | |||||
Net
increase (decrease) in cash and cash equivalents
|
$ | 9.0 | $ | (0.6 | ) |
Fiscal Year
|
||||||||||||||||||||
Total
|
2010
(remaining
nine months)
|
2011 - 2012 | 2013 - 2014 |
Thereafter
|
||||||||||||||||
Operating
leases
|
$ | 6,222 | $ | 1,442 | $ | 1,402 | $ | 776 | $ | 2,602 | ||||||||||
Purchase
commitments
|
35,293 | 29,766 | 5,527 | - | - | |||||||||||||||
Debt
obligations
|
195,000 | - | 183,000 | - | 12,000 | |||||||||||||||
Interest
on debt obligations
|
28,151 | 10,253 | 16,058 | 1,581 | 259 | |||||||||||||||
Uncertain
tax positions
|
2,747 | 2,747 | - | - | - | |||||||||||||||
Total
cash obligations
|
$ | 267,413 | $ | 44,208 | $ | 205,987 | $ | 2,357 | $ | 14,861 | ||||||||||
Standby
letters of credit
|
$ | 4,943 | $ | 4,943 |
No.
|
Description
|
||
31.1
|
Certification
of Chief Executive Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
promulgated under the Securities Exchange Act of 1934, as
amended.
|
||
31.2 |
Certification
of Chief Financial Officer pursuant to Rule 13a-15(e) and Rule 15d-15(e),
promulgated under the Securities Exchange Act of 1934, as
amended.
|
||
32.1 |
Certifications
of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
||
32.2 |
Certifications
of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
Dated: February 10,
2010
|
/s/ JOEL A. LITTMAN
|
Joel
A. Littman
Chief
Financial Officer, Treasurer and Secretary
(Duly
Authorized Officer and Chief Financial
Officer)
|